Original Articles

  1. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Di Marcantonio D, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S and Scholl C. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia, accepted.
  2. Chudasama P*, Mughal SS*, Sanders MA*, Hübschmann D*, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun 9:144, 2018
  3. Martins LR*, Bung RK*, Koch S, Richter K, Schwarzmüller L, Terhardt D, Kurtulmus B, Niehrs C, Rouhi A, Lohmann I, Pereira G, Fröhling S, Glimm H, Scholl C. Stk33 is required for spermatid differentiation and male fertility in mice. Dev Biol 433:84-93, 2018
  4. Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618, 2018
  5. Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature. 551:384-388, 2017
  6. Giessler KM*, Kleinheinz K*, Huebschmann D, Balasubramanian G, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR, Glimm H. Genetic Subclone Architecture of Tumor Clone-Initiating Cells in Colorectal Cancer. J Exp Med 214:2073-2088, 2017
  7. Ball CR*, Oppel F*, Ehrenberg KR*, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H. Succession of Transiently Active Tumor-Initiating Cell Clones in Human Pancreatic Cancer Xenografts. EMBO Mol Med 9:918-932, 2017
  8. C Zhou, E Martinez, D Di Marcantonio, N Solanki-Patel, T Aghayev, S Peri, F Ferraro, T Skorski, C Scholl, S Fröhling, S Balachandran, D L Wiest and S M Sykes. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia 31:1196-1205, 2017
  9. Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget 8:7678-7690, 2017
  10. Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Targeting fibroblast growth factor receptor 1 for treatment of soft-tissue sarcoma. Clin Cancer Res 23:962-973, 2017.
  11. Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood 127:2890-902, 2016
  12. Dubash TD, Hoffmann CM, Oppel F, Giessler KM, Bergmann S, Dieter SM, Hüllein J, Zenz T, Herbst F, Scholl C, Weichert W, Werft W, Benner A, Schmidt M, Schneider M, Glimm H, Ball CR. Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Lett 371:326-33, 2016
  13. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 30(4):937-46, 2015
  14. Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Fröhling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J. Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling. Mol Cell 59:345-358, 2015.
  15. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep 5:8535, 2015.
  16. Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res 74:7125-7136, 2014.
  17. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C,* Fröhling S.* Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124:13-23, 2014. *Equal contribution.
  18. Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C,* Fröhling S.* CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARg signaling. J Clin Invest 123:299-314, 2013. *Equal contribution.
  19. Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S,* Scholl C.* Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 209:697-711, 2012. *Equal contribution.
  20. Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci USA 109:2860-2865, 2012.
  21. Liu J, Mercher T, Scholl C, Brumme K, Gilliland DG, Zhu N. A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells. Exp Hematol 40:487-498, 2012.
  22. Fröhling S, Scholl C. STK33 kinase is not essential in KRAS-dependent cells - letter. Cancer Res 71:7716, 2012.
  23. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SA, Scholl C, Tothova Z, Attar E, Fröhling S, DePinho RA, Gilliland DG, Armstrong SA, Scadden DT.AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146:697-708, 2011.
  24. Corbacioglu A,* Scholl C,* Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Wattad M, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 28:3724-3729, 2010. *Equal contribution.
  25. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn WS, Lane SW, Scholl C, Fröhling S, Fleming MD, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Musashi-2 regulates normal hematopoisis and accelerates leukemogenesis. Nat Med 16:903-908, 2010.
  26. Koo S, Huntly B, Wang Y, Chen J, Brumme K, Ball B, McKinney-Freeman S, Yabuuchi A, Scholl C, Bansal D, Zon L, Fröhling S, Daley G, Gilliland G, Mercher T. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica 95:1642-1650, 2010.
  27. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112, 2009.
  28. Scholl C,*Fröhling S,* Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834, 2009. *Equal contribution.
  29. Kindler T, Cornejo MG, Scholl C, Liu J, Leeman DS, Haydu JE, Fröhling S, Lee BH, Gilliland DG. K-Ras G12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 112:3373-3382, 2008.
  30. Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen E, Wernig G, Erickson H, Eide C, Berger R, Bernard OA, Griffin JD, Stone RM, Meyerson M, Lee BH, Heinrich MC, Deininger MWN, Gilliland DG, Druker BJ. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111:4788-4796, 2008.
  31. Bullinger L, Döhner K, Kranz R, Stirner C, Fröhling S, Scholl C, Kim YH, Schlenk RF, Tibshirani R, Döhner H, Pollack JR. A FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 111:4490-4495, 2008.
  32. Fröhling S,* Scholl C,* Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12:501-513, 2007. *Equal contribution.
  33. Bullinger L, Rücker FG, Kurz S, Du J, Scholl C, Sander S, Corbacioglu A, Lottaz C, Krauter J, Fröhling S, Ganser A, Schlenk RF, Döhner K, Pollack JR, Döhner H. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 110:1291-1300, 2007.
  34. Scholl C,* Bansal D,* Döhner K, Eiwen K, Huntly BJ, Lee BH, Rücker FG, Schlenk RF, Bullinger L, Döhner H, Gilliland DG, Fröhling S. The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest 117:1037-1048, 2007. *Equal contribution.
  35. Bansal D, Scholl C, Fröhling S, McDowell E, Lee BH, Döhner K, Ernst P, Davidson AJ, Daley GQ, Zon LI, Gilliland DG, Huntly BJ. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proc Natl Acad Sci USA 103:16924-16929, 2006.
  36. Döhner K, Du J, Corbacioglu A, Scholl C, Schlenk RF, Döhner H. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. Haematologica 91:1569-1570, 2006.
  37. Rücker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 24:3887-3894, 2006.
  38. Fröhling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Döhner H, Gilliland DG, Levine RL, Döhner K. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, or M7. Blood 107:1242-1243, 2006.
  39. Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K. Prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 90:1626-1634, 2005.
  40. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740-3746, 2005.
  41. Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K. Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. Genes Chromosomes Cancer 42:427-432, 2005.
  42. Scholl C, Breitinger H, Schlenk RF, Döhner H, Fröhling S, Döhner K. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. Genes Chromosomes Cancer 38:274-280, 2003.
  43. Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Döhner H, Döhner K. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol 20:2480-2485, 2002.
  44. Döhner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, Scholl C, Fröhling S, Cuneo A, Tsui LC, Lichter P, Scherer SW, Döhner H. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 92:4031-4035, 1998.
  45. Fischer K, Fröhling S, Scherer SW, McAllister Brown J, Scholl C, Stilgenbauer S, Tsui LC, Lichter P, Döhner H. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 89:2036-2041, 1997.
  46. Fischer K, Scholl C, Sàlat J, Fröhling S, Schlenk R, Bentz M, Stilgenbauer S, Lichter P, Döhner H. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia. Blood 88:3962-3971, 1996.
  47. Cabot GP, Bentz M, Scholl C, Moos M, Fischer K, Lichter P, Döhner H. High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears. Cancer Genet Cytogenet 87:107-111, 1996.

Review Articles

  1. Scholl C, Gilliland DG, Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 35:336-345, 2008.
  2. Fröhling S, Scholl C, Bansal D, Huntly BJ. HOX gene regulation in acute myeloid leukemia: CDX marks the spot? Cell Cycle 6:2241-2245, 2007.
  3. Fröhling S,* Scholl C,* Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23:6285-6295, 2005. *Equal contribution.

to top